RAD51 and B-cell chronic lymphocytic leukemia: We further investigated these findings through the analysis of transcriptomic RNA-seq data of serial samples of CLL patients treated with ibrutinib [23], confirming that RAD51 RNA levels are significantly reduced in CLL patients after 1 month and 6 months of ibrutinib therapy (Fig. 5a, right panel).